Thrombolysis in pulmonary embolism: A debatable indication

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 444-451

  Goldhaber, S Z ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Pulmonary embolism; Thrombolysis

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; FIBRINOLYTIC AGENT; HEPARIN; RECOMBINANT ENZYME; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN; UROKINASE;

BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; CANCER PATIENT; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUNG ARTERY PRESSURE; LUNG EMBOLISM; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RISK ASSESSMENT; SEX DIFFERENCE; SURVIVAL; THROMBOEMBOLISM; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 0034916528     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616242     Document Type: Conference Paper

References (39)

1. A contemporary approach to thrombolytic therapy for pulmonary embolism
2. Cardiovascular risk stratification of pulmonary embolism in patients
3. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)
4. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism
5. Echocardiography Doppler in pulmonary embolism: Right ventricular dysfunction as predictor of mortality
6. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial
7. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction
8. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism
9. Free-floating thrombi in the right heart: Diagnosis, management, and prognostic indexes in 38 consecutive patients
10. Pulmonary embolism: One-year follow-up with echocardiography Doppler and five-year survival analysis
11. Troponin I in massive acute pulmonary embolism: Results of a prospective series
12. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism
13. The clinical course of pulmonary embolism
14. Management strategies and determinants of outcome in acute major pulmonary embolism: Results of a multicenter registry
15. Impact of thrombolytic treatment on the prognosis of hemodynamically stable patients with major pulmonary embolism: Results of a Multicenter Registry
16. The Urokinase Pulmonary Embolism Trial. A national cooperative study
17. Urokinase-Streptokinase Embolism Trial. Phase 2 results. A cooperative study
18. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism
19. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism
20. PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2
21. Alteplase versus heparin in acute pulmonary embolism: Randomised trial assessing right ventricular function and pulmonary perfusion
22. Recovery of regional right ventricular function after thrombolysis for pulmonary embolism
23. Lung scan evaluation of thrombolytic therapy for pulmonary embolism
24. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism
25. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors
26. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism
27. Acute pulmonary embolism treated with tissue plasminogen activator
28. A randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
29. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: A randomized controlled multicenter trial
30. Reduced dose bolus alteplase versus conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial
31. Increasing age is a major risk factor for hemorrhagic complications following pulmonary embolism thrombolysis
32. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism
33. Similarity in presentation and response to thrombolysis among women and men with pulmonary embolism
34. Attenuation over 24 hours of the efficacy of pulmonary embolism thrombolysis among cancer patients
35. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one-year follow-up
36. Hemodynamic effects of double bolus reteplase versus alteplase infusion in a massive pulmonary embolism
37. Rapid haemodynamic improvement following saruplase in recent massive pulmonary embolism
38. Recombinant staphylokinase thrombolysis in patients with acute pulmonary embolism
39. Ultrasound imaging-guided noninvasive ultrasound thrombolysis: Preclinical results